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Available online 26 June 2016While interferon alpha (IFNα) is used in several viral and cancer contexts, its efﬁcacy against ovarian cancer (OC)
is far from being incontrovertibly demonstrated and, more importantly, is hindered by heavy systemic side
effects. To overcome these issues, here we propose a strategy that allows a targeted delivery of the cytokine,
by conjugating IFNα2a with an aldehyde-modiﬁed form of hyaluronic acid (HA). The resulting HA-IFNα2a bio-
conjugate was biochemically and biologically characterized. The conjugation with HA did not substantially mod-
iﬁed both the antiviral function and the anti-proliferative activity of the cytokine. Moreover, the induction of
STAT1 phosphorylation and of a speciﬁc gene expression signature in different targets was retained. In vivo op-
tical imaging biodistribution showed that the i.p.-injected HA-IFNα2a persisted into the peritoneal cavity longer
than IFNα2a without being toxic for intraperitoneal organs, thus potentially enhancing the loco-regional thera-
peutic effect. Indeed, in OC xenograft mousemodels bioconjugate signiﬁcantly improved survival as compared to
the free cytokine. Overall, HA-IFNα2a bioconjugate disclosed an improved anticancer efﬁcacy, and can be envis-
aged as a promising loco-regional treatment for OC.







Interferon (IFN) is a family of related cytokines composed of two
classes, Type-I and Type-II, which regulate various cellular functions.
Type-I IFN consists of seven components, with the predominant forms
being IFNα that in humans comprises 12 separate proteins, and one
IFNβ [1,2]. The main IFN signaling pathway is very rapid and, after the
extracellular binding of the cytokine, results in the activation of intracel-
lular Janus kinase that phosphorylates a speciﬁc tyrosine residue in
the STAT protein, thus inducing the transcription of IFN-inducible
genes [3,4]. Different Type-I IFNs exhibit a wide range of biological
effects, because they mediate anti-viral activities, and potentiate antitu-
mor immune responses [5–8].aceutical and Pharmacological
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cules to treat different pathologies [9,10]. Indeed, IFNα is widely used in
the treatment of viral diseases (hepatitis B and C) [11], and is employed
in clinical oncology against a broad spectrum of cancers including some
hematological malignancies (hairy cell leukemia, chronic myeloid leu-
kemia, some B- and T-cell lymphomas) [12], and solid tumors (melano-
ma, renal carcinoma and Kaposi's sarcoma) [13–15]. In particular, IFNα
was the ﬁrst cytokine that received FDA approval for the treatment of
leukemia and melanoma [16].
The efﬁcacy of IFN in the treatment of ovarian cancer (OC) is still
under investigation, with encouraging results registered in a phase I/II
study [17]. Notwithstanding, the debilitating side-effects of this agent
remain a great challenge for the use of this noteworthy therapeutic po-
tential [18]. On the other hand, the use of type-I IFN has been poorly ef-
fective, largely due to toxic effects. To overcome the systemic side-
effects, several IFN delivery systems have been developed, such as the
conjugation with polyethylene glycol (PEG) [13,19], gene delivery by
albumin fusion protein [20], and microspheres for a constant release
[21,22].
Based on our previous studies with HA-protein and HA-drug conju-
gates [23–27], we hypothesized that HAylation of IFNα2a, namely thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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neal local targeted delivery of the cytokine in ovarian cancer patients.
HA was chosen because this polysaccharide is naturally present in sev-
eral body compartments, and hence fully biocompatible [28]. Moreover,
all the biological processes in which HA is involved (morphogenesis,
wound repair, inﬂammation and cancer metastasis) [29] are mediated
by HA receptors, in particular CD44 that is overexpressed in many can-
cer types including the ovarian histotype [30]. Therefore, as the CD44
receptor confers speciﬁcity and selectivity for cancerous cells being a
target site for HA-based drug delivery systems [31], the conjugation of
IFNα2a to HA is expected to decrease the toxicity induced in patients
by free IFNα2a.
In thiswork,we report the synthesis and chemical/biological charac-
terization of a novel HA-IFNα2a bioconjugate, demonstrating that it
retains a good level of antiviral and anti-proliferative activities with re-
spect to the original free cytokine, but is endowed with higher thera-
peutic efﬁcacy when administered locally in an OC intraperitoneal
xenograft model. Therefore, HA-conjugation improves the anticancer
efﬁcacy of IFNα2a and supports further testing as a promising loco-
regional approach for the treatment of ovarian cancer.
2. Materials and methods
2.1. Chemicals and drugs
Interferon-α2a (IFNα2a) was supplied by GenScript (Piscataway,
USA), while hyaluronic acid sodium salt (HA, MW 200 kDa) was
from Fidia Farmaceutici S.p.A. (Abano Terme, Italy). CH3SO3H, 1,1′-
carbonyldiimidazole (CDI), triethylamine (Et3N), 4-aminobutyraldehyde
diethyl acetal, D2O and all the other chemical reagents, including salts
and solvents, were purchased from Sigma-Aldrich (Milan, Italy).
2.2. Synthesis of HA-acetal
HA sodium salt (100 mg, 0.25 mmol) was dissolved in 10 mL of
DMSO (dimethyl sulfoxide) with CH3SO3H (81 μL, 1.25 mmol). After
complete dissolution, about 1–2 h, CDI (203 mg, 1.25 mmol) was
added, followed after 1 h by the addition of 4-aminobutyraldehyde
diethyl acetal (0.25 mmol). Et3N was used, if necessary, to raise the
pH to 8.0. The reaction mixture was left to stir at 40 °C for 12 h, and
then 1 mL of NaCl saturated solution was added drop wise, till the or-
ganic solution became opalescent. After 30 min of mixing, the polymer
was precipitated slowly by adding 20 mL of chilly ethanol. The precipi-
tate was washed with EtOH/H2O solutions at increasing percentage of
ethanol (70:30, 80:20, 90:10, v/v), and ﬁltered after each step. To better
purify the product from unreacted amine, the dried polymer was dis-
solved in water and extensively dialyzed against demineralized water
before lyophilization. The derivatization degree was determined by 1H
NMR by comparing the integration values of methylene H of acetal
moiety with the acetyl H of HA backbone.
1H NMR HA-acetal (300 MHz, D2O, 25 °C, δ): 1.10 (t, 6H, integration
value reﬂected the degree of activation, –CH(OCH2-CH3)2, acetal moiety),
1.85 (s, 3H,−NHCO-CH3, HA), 3.2–3.8 (m, GlcA, GlcNAc methylene H,
methane-H, HA).
2.3. Synthesis of N-terminal HA-IFNα2a conjugate
HA-acetal (4 mg; degree of acetal modiﬁcation 4% mol) was dis-
solved in 600 μL of 25 mM H3PO4 pH 2.1 and stirred for 1 h at 60 °C.
After cooling to room temperature (RT), the pH value of the solution
was raised to 6.0 with 0.1 M NaOH. IFNα2a (1.6 mg), previously dis-
solved in 2.4 mL of 0.1 M Na2HPO4 buffer pH 6.0, was added. After 1 h,
NaBH3CN (3mg, 21.9 μmol), dissolved in 20 μL of 0.1MNa2HPO4 buffer
pH 6.0, was added and the reaction was stirred at RT for 48 h. Then, 5
equivalent of glycine, with respect to each equivalent of aldehyde in
the starting HA, were added to the reaction mixture to quench all thealdehyde groups. The reactionwas analyzed by SEC (size-exclusion chro-
matography) with an analytical Zorbax GF-250 column (250 × 4.6 mm),
eluted with 20 mM Na2HPO4, 130 mM NaCl pH 7.0, at a ﬂow rate of
0.3 mL/min. The UV–vis detector was settled at 226 nm. The puriﬁcation
was carried out with a semi-preparative GF-250 (250 × 9.4 mm) eluted
with the samebuffer used above at theﬂowrate of 1mL/min. Thepuriﬁed
conjugate was concentrated to 10 mL and the purity was conﬁrmed
by analytical SEC. The product was extensively dialyzed against
demineralized water and lyophilized. The total protein content was
determined by the average of the results obtained by bicinchoninic acid
colorimetric assay and Abs 0.1% at 280 nm.2.4. Characterization of HA-IFNα2a
2.4.1. Near-UV circular dichroism
Near-UV CD spectra were measured using a Jasco J-810 spectropo-
larimeter equipped with a Peltier temperature control unit settled at
20 °C. Measurements of IFNα2a and HA-IFNα2a were performed in
PBS (phosphate buffered saline), pH 7.2. The concentration of protein
in all the samples was of 1 mg/mL as determined spectrophotometrically
at 280 nm. The contribution of HA was negligible, as it did not have any
absorbance at that wavelength. The spectra were collected over the
wavelength range of 250–320 nmwith an average of 2 scans. The sample
cell path length was 1 mm. The CD data were converted to mean residue
ellipticity, expressed in deg. cm2 dmol−1 by applying the following
formula:
Θ ¼ Θobs MRWð Þ=10 L C½ 
where Θ is the observed ellipticity in degrees, MRW is the mean residue
weight of the peptide (molecular weight divided by the number of
residues), [C] is the peptide concentration in mg/mL, and L is the optical
path length in centimeters.2.4.2. Determination of the site of HA conjugation
Native and HAylated IFNα2a (0.1 mg protein equiv.) were dissolved
in 6 M guanidinium·HCl, 50 mM Tris-HCl (pH 9.0) to reach a protein
concentration of 1.0 mg/mL. In order to reduce disulphide bridges,
tris(2-carboxyethyl)phosphine hydrochloride was added to the protein
solution at the ﬁnal concentration of 5 mM and the reaction mixture
was kept for 1 h at 37 °C. To the reduced protein, iodoacetamide was
added to the ﬁnal concentration of 25 mM. S-alkylation was allowed to
proceed for 30 min at 37 °C in the dark. Protein samples were puriﬁed
by RP-HPLC on a Phenomenex Jupiter C18 column (250 × 4.6 mm;
5 μm) at a ﬂow-rate of 1.0 mL/min, detection at 226 nm, eluted with a
solvent gradient of water/ACN both containing 0.1% (v/v) TFA. Gradient
0′–5% ACN, 5′–40% ACN, 25′–80% ACN, 27′–90% ACN, 30′–5% ACN.
The collected peaks were lyophilized. The reduced and S-
carboxamidomethylated samples of IFNα2a and HA-IFNα2a were dis-
solved in 8 M urea and diluted in 50 mM phosphate buffer (pH 7.9) to
reach a ﬁnal IFNα2a concentration of 1 mg/mL and urea concentration
of 0.8 M. An aliquot of trypsin of peptide sequencing purity grade was
then added at an E/S ratio of 1:50 (w/w), and the proteolysis was allowed
to proceed at 37 °C overnight. The digestion mixtures, desalted by
PepClean C-18 Spin columns (Pierce, Rockford, IL), were analyzed by an
UPLC-Q-TOF mass spectrometry method with a Grace Vydac TP C18 col-
umn (150 × 1 mm; 5 μm), maintained at 32 °C, ﬂow-rate 0.05 mL/min,
detection at 280 nm, eluted with a solvent gradient of water/ACN
both containing 0.1% formic acid. Gradient 3′–3% ACN, 24′–80% ACN,
28′–80% ACN, 29′–3% ACN, 35′–3%. Mass spectrometry data of the tryp-
tic fragments and the chromatographic peaks of native and HAylated
IFNα2a were compared to identify the site of HA conjugation.
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The following human cancer cell lines were used: HCT-15, HT-29,
LoVo and Caco-2, colorectal adenocarcinoma (CRC); IGROV-1, OVCAR-3
and SKOV-3, ovarian adenocarcinoma; PD-OVCA1 is a primary human
ovarian cancer cell line isolated and propagated in our institution [32].
CD44high and CD44low subpopulations of HCT-15 were previously isolat-
ed by immunomagnetic sorting [26]. Cells were cultured in RPMI 1640
(EuroClone, Milan, Italy) supplemented with 10% (v/v) heat-inactivated
fetal bovine serum (Gibco BRL, Paisley, UK), 2 mM L-glutamine (Lonza,
Verviers, Belgium), 10 mM HEPES (Lonza), 100 U/mL penicillin/
streptomycin (Lonza), hereafter referred as to complete medium. The
African greenmonkeykidney-derivedVEROcell linewas grown inEagle's
minimum essential medium (Sigma-Aldrich) with supplements as
describe above. Cell linesweremaintained at 37 °C in a humidiﬁed atmo-
sphere containing 5% CO2.
2.6. Antiviral assay
To determine IFNα2a-induced antiviral effects, VERO cell line was
resuspended in complete medium and seeded into 96-well ﬂat-bot-
tomed plates (1 × 105/well) with different concentrations of IFNα2a,
HA-IFNα2a and HA 200 kDa (negative control) for 24 h. At day 1, cells
were infected with vesicular stomatitis virus (VSV; MOI 1) and the
day after the viability was assessed by the ATPlite luminescence adeno-
sine triphosphate detection assay system (PerkinElmer, Zaventem,
Belgium), according to the manufacturer's instructions. The lysis solu-
tion was added to each well (50 μL), followed by addition of 50 μL of
substrate solution and ﬁnally the luminescence was counted by the
TopCount Microplate Counter (PerkinElmer). Within each experiment,
determinations were performed in triplicate and experiments were re-
peated four times. The percentage of cell survival was calculated by de-
termining the counts per second (cps) values according to the formula:
[(cpstested − cpsblank) / (cpsuntreated control − cpsblank)] × 100, with
cpsblank referring to the cps of wells that contained only medium and
ATPlite solution. The IC50 values were calculated from semi-logarithmic
dose-response curves by linear interpolation. Moreover, to visualize the
interferon activity, cells treated as described above were ﬁxed with a
mixture of methanol and acetic acid (2:1) for 30 min at 4 °C. Subse-
quently, the medium from each well was aspirated, washed twice
with milliQ water and stained over-night with crystal violet 2% (w/v)
at 4 °C. After the crystal violet solution was decanted, the plate was
rinsed with milliQ water and then dried in air.
2.7. Antiproliferative assay
To assess the IFNα2a antiproliferative activity, human colorectal and
ovarian cancer cell lines were resuspended in complete medium and
seeded into 96-well ﬂat-bottomed plates (8 × 104/well). The day after,
different concentrations of IFNα2a, HA-IFNα2a and HA 200 kDa were
added (ﬁnal volume, 100 μL/well) for 72 h. Finally, the cytotoxicity
assay was performed at day 4 by the ATPlite assay system, as reported
above. Within each experiment, determinations were performed in
triplicate and experiments were repeated 5 times for each cell line.
2.8. Flow cytometry analysis
CD44 expression in all tumor cell lineswas evaluated by ﬂow cytom-
etry, as previously reported [27]. Peripheral blood mononuclear cells
(PBMC) were isolated from anonymous healthy donor, resuspended
(1 × 106/sample) in complete medium and incubated with IFNα2a
(10 μg/mL), HA-IFNα2a (10 μg/mL in IFNα2a equivalent), HA 200 kDa
(0.323 mg/mL; negative control), or left untreated for different times
(5, 15, 30, and 60 min). At the end of treatments, the cells were ﬁxed
and permeabilized with Cytoﬁx/Cytoperm Plus Kit (BD Biosciences,
San Diego, USA), and ﬁnally labeled with a PE-conjugated mouse antihuman Stat1 monoclonal antibody (mAb, BD Biosciences). Subsequent-
ly, similar experiments were performed with HCT-15 and SKOV-3
tumor cell lines at a single timepoint (60min). All analyseswere carried
out using a ﬂow cytometer FACS-Calibur (BD Biosciences) and the
FlowJo 7.6.5 data analysis software package (TreeStar, USA).
2.9. RNA extraction, real-time PCR assay and gene expression proﬁling
Total RNAwas extracted from PBMC treated with IFNα2a (10 μg/mL)
or HA-IFNα2a (10 μg/mL in IFNα2a equivalent) for 6 h using RNeasyMini
Kit (QIAGEN, Hilden, Germany), following the manufacturer's speciﬁca-
tions. RNA was quantiﬁed by UV spectrophotometer prior to convert
into cDNAwith RT2 First Strand Kits (QIAGEN). Quantiﬁcation of gene ex-
pression was performed by real-time quantitative RT-PCR (Gene Amp®
7700 sequence detection system, PerkinElmer), wherein primers and
SYBR Green/Rox PCR master mix for IFNα2a-driven genes were synthe-
sized as “assays-on-demand” by custom service of SABiosciences
(QIAGEN). The expression of IFNα2a-guided genes in PBMC treated
with the unconjugated or HA-conjugated cytokine was determined
using the 2−ΔΔCt method [33]. Fold change values of sampleswere deter-
mined using untreated PBMC as basal controls, after normalizationwith a
pool of housekeeping genes as internal control reference (ACTB, B2M,
GAPDH, HPRT1, and RPL113A).
2.10. Ethics statement
Procedures involving animals and their carewere in conformitywith
Institutional Guidelines (D.L. 116/92 and subsequent implementing cir-
culars), and experimental protocols (project ID: 3/2012)were approved
by the local Ethical Committee of Padua University (CEASA). During in
vivo experiments, animals in all experimental groups were examined
daily for a decrease in physical activity and other signs of disease or
drug toxicity; severely ill animals were euthanized by carbon dioxide
overdose.
2.11. Mice
Six to eight week-old female severe combined immunodeﬁciency
(SCID), and BALB/c nude mice were purchased from Charles River
Laboratories (Calco, Italy), and housed in our Speciﬁc Pathogen Free
(SPF) animal facility.
2.12. Preparation of IFNα2a- and HA-IFNα2a-Cy5.5, and optical imaging
To investigate the in vivo biodistribution of free or conjugated
cytokine, IFNα2a and HA-IFNα2a conjugate were labeled with Cy5.5
dye following the protocol of Amersham CyDye™ (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) protein labeling kit. The Cy5.5 in DMSO
was added to the IFNα2a and HA-IFNα2a solutions, dissolved in 0.1 M
phosphate buffer pH 8 using a molar ratio 5:1 of Dye NHS ester-to-
IFNα2a. The conjugation reactions were performed at RT for 4 h with
mild stirring. The resulting conjugateswere puriﬁed chromatographically
using a gel ﬁltration column and a phosphate buffer as eluent. The prod-
ucts were concentrated and the buffer exchanged with PBS. The concen-
tration of the dye was calculated at its absorption maximum of 694 nm.
Themolar absorption coefﬁcient of Dye is 250,000M−1 cm−1 as reported
by the manufacturer's data sheet. The absorbance of the conjugates at
280 nm was corrected for dye contribution, approximately the 18% of
the absorbance at 694 nm. BALB/c nude and SCID mice were placed on
a low manganese diet to reduce autoﬂuorescence from normal mouse
chow, and abdominal fur was removed by depilation where requested.
Five days later, animals were injected i.p. or i.v. with Cy5.5-labeled
IFNα2a (15 μg, 1 nm of dye) or HA-IFNα2a (15 μg in IFNα2a equivalent,
1 nm of dye). In vivo biodistributionwas analyzed by total body scanning
at different time points (0, 2, 4, 6, 24 h) on isoﬂurane/oxygen anesthe-
tized animals, using the MX2 scanner (ART, Montreal, Canada). The
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ferences in biodistribution in tumor-bearing animals, the optical imaging
analysis was also performed in mice carrying intraperitoneal OC induced
by injection of PD-OVCA1 cells transduced with a lentiviral vector coding
for the ﬁreﬂy luciferase reporter gene (luc), to track tumor growth [34].
2.13. Assessment of in vivo antitumor activity and survival analysis
SCID mice were inoculated i.p. with 3 × 106 PD-OVCA1 OC cells, or
5 × 106 HCT-15 CRC cells expressing high or low levels of CD44, at day
0. Pharmacological treatments were started at day 7 from cancer cell
line injection and carried out according to a q7dx3 schedule. Each
group of animals (n = 6 mice/group) received intraperitoneally HA-
IFNα2a, IFNα2a, or was left untreated; in one experiment with PD-
OVCA1, mice received 10 μg/injection of free or conjugated IFNα2a,
while another assay was carried out with 1 μg/injection. Tumor growth
and response to therapy were monitored by recording survival in PD-
OVCA1-bearing mice, and by bioluminescence (BLI) analysis in HCT-
15-carrying animals. In this latter case, images were acquired at differ-
ent time points after in vivo cell injection using the IVIS Lumina II Imag-
ing System (PerkinElmer). Speciﬁcally, tenminutes before each imaging
session, animals were anesthetized with isoﬂurane/oxygen and admin-
istered i.p. with 150 mg/kg of D-luciferin (PerkinElmer) in DPBS. A con-
stant region of interest (ROI) was manually selected around the
abdomen of animals and the signal intensity was measured as radiance
(ph/s/cm2/sr) using the Living Image software 3.2 (PerkinElmer).
2.14. Biotolerability analysis and liver toxicity assessment
To evaluate the potential organ toxicity effects induced by bioconju-
gate or free cytokine after i.p. administration, SCID mice were injected
once i.p. with 10 μg of free or conjugated IFNα2a (3 mice/group). At
different time points thereafter (0, 8, 24, 48, and 72 h), mice sera were
collected and alanine aminotranferase (ALT) and aspartate aminotrans-
ferase (AST) levels were determined using diagnostic kits (Sclavo Diag-
nostics, Siena, Italy). At day 3, animals were sacriﬁced and abdominal
wall samples, liver, spleen, heart, kidneys and lungs were collected for
histological analysis. Tissue specimens were ﬁxed in 4% neutral-buff-
ered formalin, embedded in parafﬁn, sectioned at 4 μm and stained
with hematoxylin and eosin (H&E). Moreover, SCID mice inoculated
i.p. with 10 μg/injection of free or conjugated cytokine according to a
q7dx3 schedule, were weighed periodically throughout the experiment
up to day 30, to evaluate the overall toxicity.
2.15. Statistical analysis
Survival curves and probabilities were estimated using the Kaplan-
Meier technique. A log-rank test for comparisons or an ANOVA for re-
peated measures analysis of variance were used when required. Analy-
ses of data were done using the MedCalc (version 12) and SigmaPlot
(version 12.3) statistical packages.
3. Results
3.1. Synthesis and characterization of HA-IFNα2a
To generate a HA intermediate suitable for IFNα2a conjugation, al-
dehyde groups were grafted on the HA backbone by coupling an acetal
spacer to the carboxylic groups of the polymer. This strategy has been
previously reported [24]. To allow the preservation of HA backbone
and the obtainment of a desired percentage of aldehyde groups, the
exact degree of modiﬁcation was calculated by 1H NMR spectroscopy
by comparing the integrations of the spacer's acetal group (1.10 ppm),
and of the HA's acetyl group (1.85 ppm) signals. The HA-aldehyde syn-
thesized for this study presented a degree of aldehyde modiﬁcation of
4% mol. Thereafter, HA-acetal was activated to HA-aldehyde by a mildacid hydrolysis prior to selective N-terminal conjugation to IFNα2a.
The time-course of IFNα2a coupling was monitored by size-exclusion
chromatography (SEC). As expected, the disappearance of the peak of
free protein (tR=11.12min) over the time corresponded to the appear-
ance of a new peak (tR = 5.49 min) in agreement with the formation of
the HA-IFNα2a conjugate, which has a higher hydrodynamic volume
than IFNα2a (Fig. 1A). After an extensive dialysis, the purity of the prod-
uct was checked by SEC to ensure the elimination of unreacted protein.
The IFNα2a loading was 28% (w/w), and the reaction yield was 72%.
3.2. Characterization of HA-IFNα2a
To investigate if HAylation has produced variations on the tertiary
structure of IFNα2a, CD analysis were conducted in near-UV (250–
350 nm) region. As previously known, HA absorbs in the far-UV starting
at 215 nm due to the carbohydrate units of the polymer that have an
own absorbance, thus interfering with the IFNα2a spectra. In the
near-UV range, 250–350 nm, the shape and the construct of the CD
spectrum of a protein depends on the individual aromatic amino acid
(Phe 250–270 nm, Tyr 270–290 nm, Trp 280–300 nm) and disulphide
bonds (broad weak signals 250–350 nm), their mobility, the nature of
their environment and their spatial disposition in the protein. So,
near-UV CDwas used in this case to study changes in the protein tertia-
ry structure. IFNα2a, in its native conformation, with its 10 Phe, 5 Tyr
and 2 Trp residues, showed two main negative minima at 292 nm and
286 nm (Fig. 1B). These bands, which indicate the existence of a deﬁned
tertiary structure, were assigned to the 2 Trp(s), suggesting that these
two residues were also present in microenvironments of different
asymmetries. The other minima in the spectra resulted from Phe, Tyr
and disulphide bonds [35]. The spectrum of HA-IFNα2a showed a simi-
lar trend in all the regions, thus indicating that the tertiary protein struc-
ture was preserved. In particular, the two main negative minima were
almost superimposable suggesting that also the microenvironment
surrounding these residues was unchanged.
3.3. Identiﬁcation of HAylation site of HA-IFNα2a
To conﬁrm the site of conjugation of IFNα2a, a peptide mapping
analysis was performed using trypsin as proteolytic enzyme. The tryptic
digests were analyzed by RP-HPLC (Fig. S1). The protein sequence
coverage was about 95%, for both samples. Each peak, matching a pep-
tide fragment, was compared between the native and HAylated
IFNα2a digests in the RP-HPLC elution proﬁle (Fig. S1), and the corre-
sponding molecular mass was obtained by ESI-TOF (Table S1). The
masses of all peptide fragments of native and conjugated IFNα2a were
determined experimentally and were very similar to the theoretical ex-
pected values (Table S1). Almost all the native IFNα2a tryptic fragments
containing lysines were identiﬁed, except the dipeptide E132–K133,
which is located between two cleavage sites, K131 and K134
(ITLYLK131EK133K134YSPCAWEVVR). Nevertheless, it is important to
highlight that whether HAwas coupled to one of such lysine, the cleav-
age by trypsin would be strongly hampered by the steric entanglement
of the polymer. Also, the last lysine at the C-terminus (K164) was not
identiﬁed because trypsin cuts after R162, thus forming a small
tripeptide, SKE, which could not be determined. Since the peptide F13
[150–163] was fully identiﬁed in both native and HAylated IFNα2a, it
is conceivable that also in this case, if HA was coupled to K164, trypsin
would not be able to cut after R163 owing to the steric hindrance. The
main difference between the two samples is the peak eluted at
9.7 min, with a mass of 1369.6267 Da. The peak corresponds to the N-
terminal IFNα2a fragment (F1), which was not detected in the digested
RP proﬁle of HA-IFNα2a; no other peaks with the same molecular
weight were identiﬁed by mass analysis for HAylated IFNα2a. After
the N-terminal conjugation of IFNα2a with HA, the HAylated fragment
could not be detected by ESI-TOF, indicating that the α-amino group
at the N-terminus was selectively coupled to HA.
Fig. 1. Reaction and characterization of HA-IFNα2a. (A) Elution proﬁles of HA-IFNα2a and IFNα2a in SEC-HPLC. The peak of IFNα2a (solid line) appeared at 11.125 min, whereas the
elution proﬁles of the HA-conjugated cytokine (dotted line) disclosed a new peak at 5.495 min. (B) Comparison of the tertiary structure of native IFNα2a and HA-IFNα2a by near-UV
CD. As outlined in the experimental procedures, the spectra were recorded at the protein concentration of 1 mg/mL. The analysis demonstrated that HAylated IFNα2a (dotted line)
preserved the tertiary structure of native IFNα2a (grey line).
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To assess whether IFNα2a was still functional upon conjugation
with HA, a test of antiviral activity was performed using the free or con-
jugated cytokine. To this end, VERO cells were pretreated with scalar
doses of IFNα2a, HA-IFNα2a or HA for 24 h to induce the antiviral
state, followed by infection with the cytopathic vesicular stomatitis
virus (VSV), and assessment of cell viability the day after. IFNα2a treat-
ment before VSV infection induced in VERO cells a strong resistance to
the cytopathic effects of the virus, with an IC50 ± S.E. of 0.351 ±
0.067 μg/mL (Fig. 2A and B). Notably, the HA-conjugated cytokinemain-
tained a relevant antiviral effect that was only 2.4-fold (0.828 ±
0.108 μg/mL) lower than that exhibited by IFNα2a, thus demonstrating
that the biological activity of themolecule was impaired only in part by
conjugation to HA (Fig. 2A andB).Moreover, the antiviral activity had to
be ascribed only to the conjugated cytokine, as the 200 kDa HA carrier
was devoid of any effect, leading all cells to succumb the cytopathic ef-
fects of virus infection (Fig. 2A and B).3.5. Antiproliferative activity of HA-IFNα2a
IFNα2a is well known to exert a powerful antiproliferative activity,
which is however highly variable depending on the cell type [36]. To
identify potential suitable targets to focus on, we initially tested a
panel of ovarian and colorectal cancer cell lines for both CD44 expres-
sion (Fig. S2) and susceptibility to IFNα2a, wherein the cells were incu-
bated with two screening concentrations of the cytokine (0.05 ng/mL
and 0.5 μg/mL), and then assessed for viability. As shown in Fig. 2C,
three cell lines resulted sensitive to the antiproliferative activity of the
cytokine, namely the HCT-15 colorectal adenocarcinoma, and the
SKOV-3 and PD-OVCA1 ovarian tumors; in particular, this latter was
completely inhibited by the higher dose of IFNα2a. Subsequently, both
the HCT-15 and the PD-OVCA1 cell lines underwent titration experi-
ments with the free or conjugated cytokine, and the HA carrier as con-
trol (Fig. 2D). Results showed that IFNα2a induced a dose-dependent
growth inhibition activity in both cell lines, with a IC50 ± S.E. of
0.188 ± 0.028 μg/mL and 0.0003 ± 0.0001 μg/mL for HCT-15 and PD-
OVCA1, respectively. While the HA carrier had no effect, the bioconju-
gate also disclosed a dose-dependent growth inhibition, being the
IC50 ± S.E. for HCT-15 and PD-OVCA1 of 0.99 ± 0.263 μg/mL and
0.079 ± 0.026 μg/mL, respectively. Overall, the results of both the anti-
viral and antiproliferative experiments indicate that IFNα2a conjuga-
tion to HA reduces but not abrogate the biological activity of the
cytokine.3.6. Signaling pathway of HA-IFNα2a
The IFN signaling pathwaymainly involves the phosphorylation of the
tyrosine residues of Janus kinase (JAK) and signal transducers and activa-
tors of transcription (STAT) proteins. This is the pivotal mechanism lead-
ing to interferon-inducible gene expression [2]. A very upstream step
critical for IFNα2a signaling via the JAK-STAT pathway is the phosphory-
lation of STAT1 tyrosine 701 residue (pSTAT1), which can be determined
by a simple cytometry analysis with a speciﬁc mAb [4]. Therefore, to as-
sess the phosphorylation state of STAT1 upon incubation of responsive
cells with the free or conjugated cytokine, PBMC isolated from anony-
mous healthy donor were incubated with IFNα2a, HA-IFNα2a, HA, or
left untreated. At different time points thereafter, cells were ﬁxed and
permeabilized, and ﬁnally labeled with the anti-pSTAT1 mAb. PBMC left
untreated or treated with HA did not present STAT1 phosphorylation;
conversely, HA-IFNα2a treatment induced a marked phosphorylation of
the protein at levels comparable to those observable using the free cyto-
kine (Fig. 3A). Analysis of ﬂuorescence intensity at the different time
points tested disclosed that STAT1 phosphorylation in PBMC raised very
rapidly, to remain constant thereafter. Subsequently, similar experiments
were performed on HCT-15 and SKOV-3 tumor cell lines at a representa-
tive time point of 60min. Results of ﬂow cytometry analysis showed that
both HA-IFNα2a and IFNα2a induced similar levels of STAT1 phosphory-
lation (Fig. 3B).
3.7. Gene signature of IFNα2a and HA-IFNα2a in responding cells
Stimulation with IFNα2a is known to induce a well-deﬁned gene
signature [37]. To evaluate whether the bioconjugate retained similar
properties, PBMC isolated from anonymous healthy donor were stimu-
lated with HA-IFNα2a or the free cytokine, and the expression of
IFNα2a-stimulated genes was assessed by quantitative RT-PCR assay.
A set of 84 IFNα2a-inducible geneswere analyzed, and resulted similar-
ly expressed (Fig. 3C), as also indicated by the marked correlation be-
tween the ΔΔCt values obtained in the two experimental conditions
(Fig. 3C, inset). Such results further strength the concept that conjuga-
tion to HA did not substantially alter IFNα2a activity pattern: indeed,
only 5 out of the 84 IFN-induced genes tested were differentially regu-
lated by the conjugated cytokine, as compared to the free form.
3.8. Assessment of in vivo biodistribution of HA-IFNα2a
Initially, in vivo biodistribution of either Cy5.5-labeled IFNα2a and
HA-IFNα2a was assessed by optical imaging following both i.v. and i.p.
Fig. 2. IFNα2a-induced antiviral effects in VERO cells, and antiproliferative activity against different tumor cell lines. (A) Photograph of a microplate with VERO cells treated with free or conjugated cytokine, and stained with crystal violet. Row 1,
untreated cells; row 2, cells infected with VSV; row 3, cells incubated with IFNα2a and infected with VSV; rows 4, cells incubated with HA-IFNα2a and infected with VSV; row 5, cells incubated with HA 200 kDa and infected with VSV; row 6, cells
incubated with IFNα2a; row 7, cells incubated with HA 200 kDa. (B) Cells were incubated with escalating concentrations of IFNα2a, HA-IFNα2a or HA 200 kDa (negative control), infected with VSV 24 h later, and ﬁnally assessed for viability by the
ATPlite assay. The values of IC50 reported are the mean± S.E. of four viability experiments. For each experiment, the IC50 was calculated from each single semi-logarithmic dose-response curve by linear interpolation, and obtained values were then
averaged. Values are reported in μg/mL, and for the bioconjugate they are expressed in terms of free drug equivalents. (C)Human colorectal (LoVo, HT-29, HCT-15 and Caco-2) and ovarian (SKOV-3, PD-OVCA1, OVCAR-3 and IGROV-1) cancer cell lines
were screened for susceptibility to IFNα2a by incubationwith a high (0.5 μg/mL) and low (0.05 ng/mL) concentration of the cytokine, and the resulting growth inhibitionwas evaluated by the ATPlite assay. To note, data reported for theHCT-15 tumor
cell line refer to an unselected populationwith ~20% of CD44 expression (Fig. S2). (D) The cytotoxicity induced by escalating doses of IFNα2a, HA-IFNα2a orHA200 kDawasﬁnally studied in depth in themore IFNα2a-susceptible cell lines PD-OVCA1










Fig. 3.Analysis of STAT1 phosphorylation, and IFNα2a-inducible gene expression signature in PBMC. (A) PBMCwere treatedwith IFNα2a (orange), HA-IFNα2a (green), HA 200 kDa (red)
or left untreated (blue) for different times (5, 15, 30, and 60min), ﬁxed, permeabilized, and stainedwith a PE-labeledmouse anti human pSTAT1mAb. (B) HCT-15 and SKOV-3 tumor cell
lines were incubated with the compounds as in A, for 1 h and stained as above. Both in A and B, grey plots depict the isotype control, while data at the upper-right corner of each panel
report geo-mean values. (C) Quantitative RT-PCR analysis of 84 selected IFNα2a-inducible genes in PBMC treatedwith free (blue) or HA-conjugated IFNα2a (red). Wilcoxon Signed Rank
Test P = 0.119. The graph at the upper-left corner is a scatter plot depicting the correlation in the ΔΔCt values between PBMC treated with free or HA-conjugated IFNα2a, as assessed by
RT-PCR. The correlation coefﬁcient (R) is reported at the bottom of the panel.
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disclosed a rapid liver targeting of the bioconjugate as compared to the
free cytokine, thus essentially conﬁrming previously reported data [38].
Indeed, an almost complete preferential liver accumulation of HA-
IFNα2a was already observable 2 h after administration, and lasted up
to 24 h; conversely, theﬂuorescence signal from the free cytokine rapidly
disappeared and concentrated in the bladder, thus suggesting a potential
renal clearance (Fig. 4A). Histograms reported in Fig. 4B show the per-
centage of total photons emitted from the ROI around the liver respect
to the total body emission, and clearly disclose a different kinetics of
liver accumulation between the two compounds (P = 0.002). When
the biodistribution of Cy5.5-labeled IFNα2a and HA-IFNα2a was studied
upon i.p. administration, total body scanning disclosed that the HA-con-
jugated and free cytokine again presented different kinetics and patterns
of biodistribution (Fig. 4C). Indeed, HA-IFNα2a produced a signal that
remained conﬁned to the peritoneal cavity much longer than the free
cytokine, with an emission peak at 2 h post-injection, and a decrease
only at 24h after administration. On the contrary, the signal of the free cy-
tokine disappeared very rapidly. Indeed, histograms reported in Fig. 4D
and showing the percentage of total photons emitted from ROI around
the peritoneal cavity, clearly evidence a different kinetics of permanence
between the two compounds (P = 0.001). To conﬁrm such data also in
cancer-bearing animals at an advanced stage of disease, biodistribution
experiments were repeated in mice with a hemorrhagic and ascitic PD-
OVCA1 tumor (Fig. S4). Even in this case, kinetics and patterns ofbiodistribution appeared different in mice receiving either the free or
bound cytokine (Fig. 4E and F, P = 0.004), although the total photon
ﬂuxes in both groups were reduced, likely due to the quenching activity
of haemoglobin in ascites [39]. Thus, HA-IFNα2a appears to act as a
depot formulation that improves the bioavailability of the cytokine in
the peritoneum.
3.9. In vivo therapeutic activity of HA-IFNα2a
Before assessing the in vivo therapeutic efﬁcacy of HA-IFNα2a
against OC, additional experiments were carried out with the HCT-15
CRC cell line, which had showed to be slightly sensitive to IFNα2a
(Fig. 2C). This was donewith a double purpose: on one hand, to directly
evaluate the antitumor activity in vivo of the free and bound cytokine,
and on the other hand to gain insight about the potential relevance of
CD44 as target of the HA carrier moiety. Indeed, HCT-15 was the only
tumor cell line among those tested that allowed the isolation of two
subpopulations having a high and low expression of the receptor.
Therefore, SCID mice were inoculated i.p. with HCT-15 CD44low or
HCT-15 CD44high cell lines, and treated locally with 10 μg/injection
(q7dx3 schedule) of free or HA-conjugate IFNα2a. The therapeutic
impact of the different treatments was evaluated by BLI, as the total
photon ﬂux is strictly correlated with tumor growth [40]. As illustrated
in Fig. 5A, HA-IFNα2a signiﬁcantly restrained the growth of HCT-15
CD44high tumors, while the free cytokine had no effect. Conversely, in
Fig. 4.Biodistribution analysis of Cy5.5-labeledHA-IFNα2a and IFNα2a in BALB/c nude and SCIDmice. (A) BALB/c nudemicewere injected i.v.with Cy5.5-labeledHA-IFNα2a (upper panels) or
IFNα2a (lower panels). Biodistribution kinetics of the compoundswas assessed byﬂuorescence optical imaging as total body scanningwith a 670nm laser and a 693LPﬁlter; spatial resolution/
scan step was ﬁxed at 1.5 mm, exposure time was 0.5 s, and laser power was automatically adjusted for each scan session. The ﬁgure shows one representative experiment of three that
produced similar results. (B) The vertical histograms represent the percentage of total photons emitted from ROI around the liver respect to the total body emission. Data are expressed as
photon ﬂux and quantiﬁed as photon × second−1. Three mice per group were analyzed and data are reported as mean ± S.D. (C) SCID mice were injected i.p. with Cy5.5-labeled HA-
IFNα2a (upper panels) or IFNα2a (lower panels). Biodistribution kinetics of the compounds was assessed as reported in (A). (D) The vertical histograms refer to the total photons emission
from mouse abdominal ROI. Data and mice as in (B). (E) Experiments and data analysis shown in (C) and (D) were repeated in mice bearing an ascitic PD-OVCA1 tumor (Fig. S3).
86 I.M. Montagner et al. / Journal of Controlled Release 236 (2016) 79–89mice injectedwith the cell line expressing low levels of the receptor nor
the HA-IFNα2a or IFNα2a produced a therapeutic beneﬁt (Fig. 5B). As a
conﬁrmation, the therapeutic activity of free and bound cytokine wasalso evaluated in an OC model induced by the i.p. injection of PD-
OVCA1 tumor cells. In a ﬁrst experiment, mice were treated locally
with 10 μg/injection (q7dx3 schedule) of free or HA-conjugated
Fig. 5. In vivo IFNα2a antitumor activity. (A) and (B) BLI of mice inoculatedwith 5 × 106 bioluminescent (A) HCT-15 CD44high or (B)HCT-15 CD44low cells, and treatedwith 10 μg/injection
(q7dx3 schedule) of IFNα2a, HA-IFNα2a (in IFNα2a equivalents), or left untreated (UNT). Panels show three representative mice/group 30 days after tumor injection. Under each panel,
the vertical plot reports the cumulative total photons emission at different time points (6, 14, 21, 30 days). Six mice per group were analyzed, and data represent means± SD. Statistical
analysis: ANOVA for repeated measures analysis of variance. (C) and (D) Kaplan-Meier survival curves of PD-OVCA1-bearing mice treated with 10 μg/injection or 1 μg/injection,
respectively, of IFNα2a, HA-IFNα2a (in IFNα2a equivalents) or left untreated (UNT). In both cases, the administration schedule was q7dx3. Statistical analysis and median survival
time are reported in table at the bottom of each panel.
87I.M. Montagner et al. / Journal of Controlled Release 236 (2016) 79–89IFNα2a through the i.p. route. Results of Fig. 5C show that HA-IFNα2a
loco-regional treatment (median survival, 41 day) evidenced a relevant
growth inhibitory effect and induced an increased survival compared to
untreated mice (median survival, 30 day; P = 0.0006). Although the
HA-IFNα2a led to a higher survival compared to free cytokine (mediansurvival, 35 day), data did not reach a statistical signiﬁcance (P = 0.1).
Therefore, to highlight the targeting properties of the bioconjugate
a second experimentwas carried out, where 10-fold less (1 μg/injection,
q7dx3 schedule) of free or bound cytokine was administered (Fig. 5D).
Results showed that PD-OVCA1-bearing mice treated with HA-IFNα2a
88 I.M. Montagner et al. / Journal of Controlled Release 236 (2016) 79–89(median survival, 51 day) exhibited an increased survival compared to
both untreated control mice (median survival, 32 day; P = 0.002) and
free IFNα2a-treated mice (median survival, 43 day; P = 0.01)
3.10. Biotolerability and liver toxicity analysis
In a clinical setting, locally administered antitumor therapies must
be well tolerated. To assess whether the free or bound forms of the
cytokine induced toxic effects on the mesothelial lining and peritoneal
organs, three groups of SCID mice were injected once i.p. with the bio-
conjugate or free IFNα2a. Full thickness specimens of the abdominal
wall, and liver, spleen, heart, kidneys and lungs were collected at day
3 after treatment, and analyzed histologically. All samples did not
show inﬂammatory inﬁltrates or morphological alterations (Fig. S4),
even in the case of HA-IFNα2a administration, where the cytokine
persist longer in the peritoneal cavity. Moreover, AST and ALT liver en-
zymes activity in the plasma of treated mice turned out to be under the
detection threshold level of the diagnostic kits employed, thus indicat-
ing the absence of direct liver toxicity (data not show). Additionally,
for the assessment of overall toxicity SCID mice were treated with bio-
conjugate or free cytokine according to a q7dx3 schedule, and the
weight was periodically recorded over a 1-month period. No weight
loss was observed, nor differences in average body weight between
treated and untreated mice (Fig. S5).
4. Discussion
OC imperatively needs new treatmentmodalities because at present
there are no decisive therapeutic solutions. This condition could beneﬁt
of a targeted therapy, because the peritoneum-plasma barrier can allow
a local delivery of drugs, thus potentially reducing heavy systemic side
effects.
Here, we took advantage of our expertise in HA-based bioconjugates
to improve also the direct delivery of IFNα2a to the peritoneal cavity.
This strategy has the potentiality to improve the treatment of OC, in par-
ticular in terms of safety and tolerability. Indeed, we previously showed
that the loco-regional administration of a paclitaxel-HA conjugate
outperformed the free drug in terms of tolerability and therapeutic efﬁ-
cacy in an OC preclinical setting [27]. In addition, the bioconjugate was
also very efﬁcient towards different models of peritoneal carcinomato-
sis [26], and bladder cancer both in experimental [25] and clinical con-
ditions [41]. Moreover, another HA bioconjugate (SN38-HA) has been
successfully tested in a mouse model of CRC peritoneal carcinomatosis
[42] and OC [43]. Therefore, HA can act as a suitable carrier being
endowed with the capability to selectively target tumor cells through
the binding to CD44. This receptor is over-expressed in many cancers,
including the ovarian histotype as exempliﬁed by cytometry results
outlined in this work and previously [26,43]. Moreover, it has been
shown that HA has per se the capacity to reduce postoperative and
disease-related adhesions without impacting the metastatic potential
of tumor cells [44]. In addition, it can exert a relevant depot effect [45,
46]. In the case of HA conjugation to proteins, it is mandatory to exploit
a site-selective conjugation approach to avoid the risk of cross-linking.
In this regards, an innovative HA-aldehyde was previously designed
and studied for yielding a site-selective N-terminus protein [24].
Remarkably, the conjugatemaintained the anti-viral and anti-prolifer-
ative activities of the free cytokine. In addition, the JAK-STAT signaling
pathway was similarly activated by the free and bound form of IFNα2a,
while the gene expression proﬁle induced by HA-IFNα2a slightly
diverged for only 5 out of the 84 genes activated by the free cytokine,
thus suggesting a substantially identical pattern of gene mobilization.
Moreover, the preserved pleiotropic activities of the cytokinewere imple-
mented by the intrinsic targeting properties of HA. The in vivo
biodistribution and fate of HA-IFNα2a differed from that of IFNα2a, and
was dictated by the hyaluronan moiety both in healthy and tumor-bear-
ing mice. Indeed, i.p.-injected HA-IFNα2a remained into the peritonealcavity longer than IFNα2a. This kind of “depot effect” ensures a prolonged
cytokine release without inducing local adverse reactions, as shown by
the lack of histological alterations in intraperitoneal and peripheral
organs. In this regard,wepreviously demonstrated thatHA-bioconjugates
are absolutely devoid of any proinﬂammatory [27]. The improved bio-
availability and the targeting properties of the HA-IFNα2a conjugate
entailed an enhanced therapeutic efﬁcacy, as demonstrated in the
proof-of-principle therapeutic experiment involving CRC subpopulations
expressing high or low levels of CD44 receptor. The lack of therapeutic
beneﬁt of both the free and conjugated cytokine against HCT-15
CD44low tumors in conjunctionwith the efﬁcacy of theHA-IFNα2a against
HCT-15 CD44high counterparts, incontrovertibly supports the notion that
HA-mediated retargeting of CD44 can make effective a cytokine other-
wise devoid of therapeutic impact. Accordingly, in OC xenograft mouse
models the HA-IFNα2a bioconjugate signiﬁcantly prolonged mice long-
term survival with respect to the free cytokine. In particular, this im-
proved therapeutic effectwas evidencedwith the lowest dose of cytokine,
as a proof-of-concept of the ﬁne targeting capacity of the HA moiety.
Conversely, due to the great sensitivity of PD-OVCA1 cells to the cytokine,
the administration of HA-IFNα2a and IFNα2a at high dose completely
abrogated any difference in the treatment outcome.
While not relevant for OC treatment, for the sake of completeness
the biodistribution of the bioconjugate given i.v. was also investigated.
As previously demonstrated [38], i.v.-injected bioconjugate disclosed a
marked accumulation in the liver, mainly due to the presence of the
HARE receptors in this district [47], and was not toxic. Because of this
peculiar accumulation of the i.v.-administered HA-IFNα2a, the biocon-
jugate can be envisaged also as a safe and targeted treatment for liver
diseases, especially HBV or HCV infections.
Overall, present data envisage that the conjugation of IFNα2a to HA
can provide an effective strategy to improve the loco-regional treatment
of OC, thus supporting its further testing in a clinical setting.
5. Conclusion
This study demonstrated that the site-selective conjugation of
IFNα2a with HA resulted in the construction of an efﬁcient therapeutic
agent for OC treatment. Several tests demonstrated that HA-IFNα2a
preserved the protein activity thanks to precise conjugation chemistry
based on the use of a HA-aldehyde derivative. The conjugation allowed
to conﬁne the drug to the peritoneal cavity, thus acting as a depot
formulation that improved the bioavailability of the cytokine in the
peritoneum. In the xenograft mouse models, HA-IFNα2a exhibited a
superior antitumor activity in comparison to the free cytokine. These re-
sults conﬁrm that the project's aimwas achieved and encourage further
investigations.
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